{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:04:13Z","timestamp":1789524253013,"version":"build-2803163510"},"reference-count":100,"publisher":"Elsevier","isbn-type":[{"value":"9780128097144","type":"print"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/bs.irn.2017.01.005","type":"book-chapter","created":{"date-parts":[[2017,2,15]],"date-time":"2017-02-15T21:30:13Z","timestamp":1487194213000},"page":"381-405","source":"Crossref","is-referenced-by-count":20,"title":["Treatment of Older Parkinson's Disease"],"prefix":"10.1016","author":[{"given":"Abhishek","family":"Lenka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekharapillai","family":"Padmakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramod K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/bs.irn.2017.01.005_bb0010","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1111\/j.1445-5994.2011.02499.x","article-title":"Use of antipsychotic medications in patients with Parkinson's disease at Auckland City Hospital","volume":"42","author":"Bloomfield","year":"2012","journal-title":"Internal Medicine Journal"},{"key":"10.1016\/bs.irn.2017.01.005_bb0015","series-title":"Neuropsychiatric symptoms of movement disorders","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-3-319-09537-0_6","article-title":"Psychosis in Parkinson's disease","author":"Bountouni","year":"2015"},{"issue":"2","key":"10.1016\/bs.irn.2017.01.005_bb0020","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3233\/JPD-150742","article-title":"Age limits for deep brain stimulation of subthalamic nuclei in Parkinson's disease","volume":"6","author":"Bouwyn","year":"2016","journal-title":"Journal of Parkinson's Disease"},{"issue":"2","key":"10.1016\/bs.irn.2017.01.005_bb0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/bs.irn.2017.01.005_bb0030","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1517\/14656566.2014.936848","article-title":"Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies","volume":"15","author":"Broadstock","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"5","key":"10.1016\/bs.irn.2017.01.005_bb0035","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1185\/030079902125000813","article-title":"Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: A case series","volume":"18","author":"Bullock","year":"2002","journal-title":"Current Medical Research and Opinion"},{"issue":"3","key":"10.1016\/bs.irn.2017.01.005_bb0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","article-title":"Non-motor symptoms of Parkinson's disease: Diagnosis and management","volume":"5","author":"Chaudhuri","year":"2006","journal-title":"Lancet Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2017.01.005_bb9000","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1212\/WNL.0b013e3181ec7fac","article-title":"REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century","volume":"75","author":"Claassen","year":"2010","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/bs.irn.2017.01.005_bb0045","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: A review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/bs.irn.2017.01.005_bb0050","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/1545968314567150","article-title":"The effects of highly challenging balance training in elderly with Parkinson's disease: A randomized controlled trial","volume":"29","author":"Conradsson","year":"2015","journal-title":"Neurorehabilitation and Neural Repair"},{"key":"10.1016\/bs.irn.2017.01.005_bb0055","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/362572","article-title":"Risk of falls in Parkinson's disease: A cross-sectional study of 160 patients","volume":"2012","author":"Contreras","year":"2012","journal-title":"Parkinson's Disease"},{"issue":"13","key":"10.1016\/bs.irn.2017.01.005_bb0060","first-page":"132","article-title":"Older candidates for subthalamic deep brain stimulation in Parkinson's disease have a higher incidence of psychiatric serious adverse events","volume":"8","author":"Cozac","year":"2016","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/bs.irn.2017.01.005_bb0065","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: A randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/bs.irn.2017.01.005_bb0070","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12876-015-0366-3","article-title":"Chronic constipation in the elderly: A primer for the gastroenterologist","volume":"15","author":"De Giorgio","year":"2015","journal-title":"BMC Gastroenterology"},{"issue":"6","key":"10.1016\/bs.irn.2017.01.005_bb0075","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson's disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2017.01.005_bb0080","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jamaneurol.2014.1272","article-title":"Effect of advancing age on outcomes of deep brain stimulation for Parkinson disease","volume":"71","author":"DeLong","year":"2014","journal-title":"JAMA Neurology"},{"issue":"17","key":"10.1016\/bs.irn.2017.01.005_bb0085","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1212\/01.wnl.0000260059.77107.c2","article-title":"Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?","volume":"68","author":"Derost","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2017.01.005_bb0090","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp-2013-306439","article-title":"Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: A double-blind, placebo-controlled, randomised clinical trial","volume":"85","author":"Devos","year":"2014","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"4","key":"10.1016\/bs.irn.2017.01.005_bb0095","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archneur.60.4.529","article-title":"Parkinson disease with old-age onset: A comparative study with subjects with middle-age onset","volume":"60","author":"Diederich","year":"2003","journal-title":"Archives of Neurology"},{"issue":"14","key":"10.1016\/bs.irn.2017.01.005_bb0100","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1001\/archinte.160.14.2101","article-title":"Depression is a risk factor for noncompliance with medical treatment","volume":"160","author":"DiMatteo","year":"2000","journal-title":"Archives of Internal Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2017.01.005_bb0105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11940-014-0285-6","article-title":"Anxiety and depression in Parkinson's disease","volume":"16","author":"Djamshidian","year":"2014","journal-title":"Current Treatment Options in Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2017.01.005_bb0110","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1176\/appi.ajp.2011.10111669","article-title":"Cognitive-behavioral therapy for depression in Parkinson's disease: A randomized, controlled trial","volume":"168","author":"Dobkin","year":"2011","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/bs.irn.2017.01.005_bb0115","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/bs.irn.2017.01.005_bb0120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0735-6757(00)90023-8","article-title":"Emergency department presentations of patients with Parkinson's disease","volume":"18","author":"Factor","year":"2000","journal-title":"The American Journal of Emergency Medicine"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2017.01.005_bb0125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","article-title":"Epidemiology of psychosis in Parkinson's disease","volume":"289","author":"F\u00e9nelon","year":"2010","journal-title":"Journal of the Neurological Sciences"},{"issue":"Pt. 4","key":"10.1016\/bs.irn.2017.01.005_bb0130","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors","volume":"123","author":"F\u00e9nelon","year":"2000","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.irn.2017.01.005_bb0135","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2012.03866.x","article-title":"Summary of the recommendations of the EFNS\/MDS-ES review on therapeutic management of Parkinson's disease","volume":"20","author":"Ferreira","year":"2013","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2017.01.005_bb0140","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/mds.10342","article-title":"Entacapone-induced hepatotoxicity and hepatic dysfunction","volume":"17","author":"Fisher","year":"2002","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2017.01.005_bb0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/nau.20371","article-title":"Update on the neurology of Parkinson's disease","volume":"26","author":"Fowler","year":"2007","journal-title":"Neurourology and Urodynamics"},{"issue":"6","key":"10.1016\/bs.irn.2017.01.005_bb0150","first-page":"114","article-title":"A review of sleep and its disorders in patients with Parkinson's disease in relation to various brain structures","volume":"8","author":"French","year":"2016","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/bs.irn.2017.01.005_bb0155","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/1531-8257(200003)15:2<201::AID-MDS1001>3.0.CO;2-D","article-title":"Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease","volume":"15","author":"Friedman","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2017.01.005_bb0160","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ncl.2004.01.004","article-title":"The perioperative management of Parkinson's disease revisited","volume":"22","author":"G\u00e1lvez-Jim\u00e9nez","year":"2004","journal-title":"Neurologic Clinics"},{"issue":"9","key":"10.1016\/bs.irn.2017.01.005_bb0165","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00702-013-1001-5","article-title":"The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease","volume":"120","author":"Giladi","year":"2013","journal-title":"Journal of Neural Transmission"},{"issue":"1","key":"10.1016\/bs.irn.2017.01.005_bb0170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s007020050005","article-title":"Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease","volume":"107","author":"Giladi","year":"2000","journal-title":"Journal of Neural Transmission"},{"issue":"5","key":"10.1016\/bs.irn.2017.01.005_bb0175","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1212\/01.wnl.0000233980.25978.9d","article-title":"Excessive daytime sleepiness in Parkinson disease: Is it the drugs or the disease?","volume":"67","author":"Gjerstad","year":"2006","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2017.01.005_bb0180","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1212\/01.wnl.0000210692.95595.1c","article-title":"Safety of rasagiline in elderly patients with Parkinson disease","volume":"66","author":"Goetz","year":"2006","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2017.01.005_bb0185","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/mds.870120303","article-title":"Clinical and pharmacological differences in early- versus late-onset Parkinson's disease","volume":"12","author":"Gomez Arevalo","year":"1997","journal-title":"Movement Disorders"},{"issue":"10","key":"10.1016\/bs.irn.2017.01.005_bb0190","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.amjmed.2007.02.023","article-title":"Orthostatic hypotension in the elderly: Diagnosis and treatment","volume":"120","author":"Gupta","year":"2007","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/bs.irn.2017.01.005_bb0195","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1749-6632.2009.05118.x","article-title":"The progression of pathology in Parkinson's disease","volume":"1184","author":"Halliday","year":"2010","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2017.01.005_bb9005","first-page":"288","article-title":"Amantadine-induced livedo reticularis: A report of two cases","volume":"5","author":"Hayes","year":"2006","journal-title":"Journal of Drugs in Dermatology"},{"issue":"3","key":"10.1016\/bs.irn.2017.01.005_bb0200","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","article-title":"Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"15","author":"Henderson","year":"2016","journal-title":"Lancet Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2017.01.005_bb0205","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.parkreldis.2014.06.023","article-title":"Natural history of falls in a population-based cohort of patients with Parkinson's disease: An 8-year prospective study","volume":"20","author":"Hiorth","year":"2014","journal-title":"Parkinsonism & Related Disorders"},{"issue":"3","key":"10.1016\/bs.irn.2017.01.005_bb0210","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2017.01.005_bb0215","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.parkreldis.2009.02.009","article-title":"Osteoporosis in Parkinson's disease","volume":"15","author":"Invernizzi","year":"2009","journal-title":"Parkinsonism & Related Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2017.01.005_bb0220","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson's disease: Clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"9","key":"10.1016\/bs.irn.2017.01.005_bb0225","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/pds.2016","article-title":"Risk of serious ventricular arrhythmia and sudden cardiac death in a cohort of users of domperidone: A nested case-control study","volume":"19","author":"Johannes","year":"2010","journal-title":"Pharmacoepidemiology and Drug Safety"},{"issue":"4","key":"10.1016\/bs.irn.2017.01.005_bb0230","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00702-012-0914-8","article-title":"Urological problems in Parkinson's disease: Clinical aspects","volume":"120","author":"Jost","year":"2013","journal-title":"Journal of Neural Transmission"},{"issue":"9","key":"10.1016\/bs.irn.2017.01.005_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161689","article-title":"Comparing the incidence of falls\/fractures in Parkinson's disease patients in the US population","volume":"11","author":"Kalilani","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/bs.irn.2017.01.005_bb0240","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/mds.20942","article-title":"Excess burden of constipation in Parkinson's disease: A pilot study","volume":"21","author":"Kaye","year":"2006","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2017.01.005_bb0245","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/11539720-000000000-00000","article-title":"Excessive daytime sleepiness in patients with Parkinson's disease","volume":"25","author":"Knie","year":"2011","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/bs.irn.2017.01.005_bb0250","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.parkreldis.2014.07.004","article-title":"Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life","volume":"20","author":"Lawson","year":"2014","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1016\/bs.irn.2017.01.005_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.parkreldis.2015.11.018","article-title":"Interactions of visual hallucinations, rapid eye movement sleep behavior disorder and cognitive impairment in Parkinson's disease: A review","volume":"22","author":"Lenka","year":"2016","journal-title":"Parkinsonism & Related Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2017.01.005_bb0260","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/0891988712464823","article-title":"Cognitive impairment in Parkinson disease: Impact on quality of life, disability, and caregiver burden","volume":"25","author":"Leroi","year":"2012","journal-title":"Journal of Geriatric Psychiatry and Neurology"},{"issue":"21","key":"10.1016\/bs.irn.2017.01.005_bb0265","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1212\/WNL.0000000000002145","article-title":"Cognitive training in Parkinson disease: A systematic review and meta-analysis","volume":"85","author":"Leung","year":"2015","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2017.01.005_bb0270","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.parkreldis.2015.03.024","article-title":"Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease","volume":"21","author":"Martinez-Martin","year":"2015","journal-title":"Parkinsonism & Related Disorders"},{"issue":"3","key":"10.1016\/bs.irn.2017.01.005_bb0275","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mds.23462","article-title":"The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease","volume":"26","author":"Martinez-Martin","year":"2011","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2017.01.005_bb0280","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1146\/annurev.med.50.1.317","article-title":"Postural hypotension: Causes, clinical features, investigation, and management","volume":"50","author":"Mathias","year":"1999","journal-title":"Annual Review of Medicine"},{"key":"10.1016\/bs.irn.2017.01.005_bb0285","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.sleep.2014.09.011","article-title":"Melatonin therapy for REM sleep behavior disorder: A critical review of evidence","volume":"16","author":"McGrane","year":"2015","journal-title":"Sleep Medicine"},{"issue":"10","key":"10.1016\/bs.irn.2017.01.005_bb0290","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2017.01.005_bb0295","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.phrs.2011.11.009","article-title":"The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease","volume":"65","author":"Mokhles","year":"2012","journal-title":"Pharmacological Research"},{"issue":"1","key":"10.1016\/bs.irn.2017.01.005_bb0300","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1468-1331.2001.00168.x","article-title":"Twelve-month safety of entacapone in patients with Parkinson's disease","volume":"8","author":"Myllyl\u00e4","year":"2001","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2017.01.005_bb0305","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12028-008-9125-4","article-title":"The parkinsonism-hyperpyrexia syndrome","volume":"10","author":"Newman","year":"2009","journal-title":"Neurocritical Care"},{"issue":"8","key":"10.1016\/bs.irn.2017.01.005_bb0310","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.parkreldis.2012.06.022","article-title":"Duodopa\u00ae treatment for advanced Parkinson's disease: A review of efficacy and safety","volume":"18","author":"Nyholm","year":"2012","journal-title":"Parkinsonism & Related Disorders"},{"issue":"1","key":"10.1016\/bs.irn.2017.01.005_bb0315","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.parkreldis.2012.06.009","article-title":"Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: Age-relationship to safety and tolerability","volume":"19","author":"Oertel","year":"2013","journal-title":"Parkinsonism & Related Disorders"},{"issue":"15","key":"10.1016\/bs.irn.2017.01.005_bb0320","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1212\/WNL.0000000000002461","article-title":"Age at onset and Parkinson disease phenotype","volume":"86","author":"Pagano","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2017.01.005_bb0325","first-page":"391","article-title":"Excessive daytime sleepiness","volume":"79","author":"Pagel","year":"2009","journal-title":"American Family Physician"},{"issue":"2","key":"10.1016\/bs.irn.2017.01.005_bb0330","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1037\/0882-7974.7.2.252","article-title":"Medication adherence behaviors in older adults: Effects of external cognitive supports","volume":"7","author":"Park","year":"1992","journal-title":"Psychology and Aging"},{"issue":"1","key":"10.1016\/bs.irn.2017.01.005_bb0335","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1179\/174313208X338052","article-title":"Entacapone in elderly parkinsonian patients experiencing levodopa-related wearing-off: A pilot study","volume":"31","author":"Pellicano","year":"2009","journal-title":"Neurological Research"},{"issue":"6","key":"10.1016\/bs.irn.2017.01.005_bb0340","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/jnnp.73.6.636","article-title":"Apathy in Parkinson's disease","volume":"73","author":"Pluck","year":"2002","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"Suppl. 6","key":"10.1016\/bs.irn.2017.01.005_bb0345","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1002\/mds.10567","article-title":"Psychosis in Parkinson's disease","volume":"18","author":"Poewe","year":"2003","journal-title":"Movement Disorders"},{"issue":"5","key":"10.1016\/bs.irn.2017.01.005_bb0350","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":"Clozapine in drug induced psychosis in Parkinson's disease: A randomised, placebo controlled study with open follow up","volume":"75","author":"Pollak","year":"2004","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"5","key":"10.1016\/bs.irn.2017.01.005_bb0355","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1532-5415.1975.tb00187.x","article-title":"Visual hallucinations and delirium during treatment with amantadine (Symmetrel)","volume":"23","author":"Postma","year":"1975","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1016\/bs.irn.2017.01.005_bb0360","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson's disease: A systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Movement Disorders"},{"key":"10.1016\/bs.irn.2017.01.005_bb0370","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1002\/mds.22806","volume":"25","author":"RBD","year":"2010","journal-title":"Movement Disorders"},{"issue":"6","key":"10.1016\/bs.irn.2017.01.005_bb0375","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/mds.1204","article-title":"Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial","volume":"16","author":"Reading","year":"2001","journal-title":"Movement Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2017.01.005_bb0380","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/14656566.2015.997211","article-title":"Management of constipation in Parkinson's disease","volume":"16","author":"Rossi","year":"2015","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"10","key":"10.1016\/bs.irn.2017.01.005_bb0385","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1212\/01.WNL.0000144198.26309.D8","article-title":"Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years","volume":"63","author":"Russmann","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2017.01.005_bb0390","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fneur.2013.00064","article-title":"The management of orthostatic hypotension in Parkinson's disease","volume":"4","author":"S\u00e1nchez-Ferro","year":"2013","journal-title":"Frontiers in Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2017.01.005_bb0395","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1586\/ern.11.43","article-title":"Intensive voice treatment in Parkinson's disease: Lee Silverman Voice Treatment","volume":"11","author":"Sapir","year":"2011","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"4","key":"10.1016\/bs.irn.2017.01.005_bb0400","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1044\/1092-4388(2007\/064)","article-title":"Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: Acoustic and perceptual findings","volume":"50","author":"Sapir","year":"2007","journal-title":"Journal of Speech, Language, and Hearing Research"},{"issue":"12","key":"10.1016\/bs.irn.2017.01.005_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0015298","article-title":"Amantadine for dyskinesias in Parkinson's disease: A randomized controlled trial","volume":"5","author":"Sawada","year":"2010","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/bs.irn.2017.01.005_bb0410","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3928\/0098-9134-20040701-08","article-title":"Medication non-adherence among older adults: A review of strategies and interventions for improvement","volume":"30","author":"Schlenk","year":"2004","journal-title":"Journal of Gerontological Nursing"},{"key":"10.1016\/bs.irn.2017.01.005_bb0415","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1755-5949.2010.00182.x","article-title":"Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia","volume":"16","author":"Schmitt","year":"2010","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"8","key":"10.1016\/bs.irn.2017.01.005_bb0420","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.parkreldis.2010.06.009","article-title":"High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease","volume":"16","author":"Schnitzler","year":"2010","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1016\/bs.irn.2017.01.005_bb0425","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1474-4422(05)70098-3","article-title":"Entacapone in the treatment of Parkinson's disease","volume":"4","author":"Schrag","year":"2005","journal-title":"Lancet Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2017.01.005_bb0430","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/jnnp.63.5.584","article-title":"Prevalence of orthostatic hypotension in Parkinson's disease","volume":"63","author":"Senard","year":"1997","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"2","key":"10.1016\/bs.irn.2017.01.005_bb0435","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1545968314537559","article-title":"Technology-assisted balance and gait training reduces falls in patients with Parkinson's disease: A randomized controlled trial with 12-month follow-up","volume":"29","author":"Shen","year":"2014","journal-title":"Neurorehabilitation and Neural Repair"},{"issue":"10","key":"10.1016\/bs.irn.2017.01.005_bb0440","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1517\/14656566.7.10.1399","article-title":"The levodopa wearing-off phenomenon in Parkinson's disease: Pharmacokinetic considerations","volume":"7","author":"Stocchi","year":"2006","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"1","key":"10.1016\/bs.irn.2017.01.005_bb0445","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.parkreldis.2013.09.025","article-title":"The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort","volume":"20","author":"Szewczyk-Krolikowski","year":"2014","journal-title":"Parkinsonism & Related Disorders"},{"issue":"Suppl. 1","key":"10.1016\/bs.irn.2017.01.005_bb0450","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S1353-8020(02)00122-0","article-title":"A collaborative study on the malignant syndrome in Parkinson's disease and related disorders","volume":"9","author":"Takubo","year":"2003","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1016\/bs.irn.2017.01.005_bb0455","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1445-5994.2006.01123.x","article-title":"Reasons for admission to hospital for Parkinson's disease","volume":"36","author":"Temlett","year":"2006","journal-title":"Internal Medicine Journal"},{"issue":"2","key":"10.1016\/bs.irn.2017.01.005_bb0460","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/01.TGR.0000318899.87690.44","article-title":"Speech and swallowing in Parkinson's disease","volume":"24","author":"Tjaden","year":"2008","journal-title":"Topics in Geriatric Rehabilitation"},{"issue":"9","key":"10.1016\/bs.irn.2017.01.005_bb0465","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.parkreldis.2015.06.012","article-title":"Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease\u2014Clinical practice recommendations","volume":"21","author":"Trenkwalder","year":"2015","journal-title":"Parkinsonism & Related Disorders"},{"issue":"5","key":"10.1016\/bs.irn.2017.01.005_bb0470","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2165\/00002512-199813050-00002","article-title":"Monoamine oxidase inhibitors. A perspective on their use in the elderly","volume":"13","author":"Volz","year":"1998","journal-title":"Drugs & Aging"},{"issue":"6","key":"10.1016\/bs.irn.2017.01.005_bb0475","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/jnnp.72.6.721","article-title":"Incidence and prediction of falls in Parkinson's disease: A prospective multidisciplinary study","volume":"72","author":"Wood","year":"2002","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"9","key":"10.1016\/bs.irn.2017.01.005_bb0480","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/mds.20485","article-title":"Emergency hospital admissions in idiopathic Parkinson's disease","volume":"20","author":"Woodford","year":"2005","journal-title":"Movement Disorders"},{"issue":"7","key":"10.1016\/bs.irn.2017.01.005_bb0485","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00702-010-0425-4","article-title":"Transdermal rotigotine for the perioperative management of Parkinson's disease","volume":"117","author":"W\u00fcllner","year":"2010","journal-title":"Journal of Neural Transmission"},{"issue":"5","key":"10.1016\/bs.irn.2017.01.005_bb0490","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40035-016-0058-0","article-title":"Meta-analysis of risk factors for Parkinson's disease dementia","volume":"5","author":"Xu","year":"2016","journal-title":"Translational Neurodegeneration"},{"key":"10.1016\/bs.irn.2017.01.005_bb0495","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11255-011-9969-y","article-title":"Urinary tract dysfunction in Parkinson's disease: A review","volume":"44","author":"Yeo","year":"2012","journal-title":"International Urology and Nephrology"},{"issue":"10","key":"10.1016\/bs.irn.2017.01.005_bb0500","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.clineuro.2013.07.027","article-title":"The association between non-motor symptoms in Parkinson's disease and age at onset","volume":"115","author":"Zhou","year":"2013","journal-title":"Clinical Neurology and Neurosurgery"}],"container-title":["International Review of Neurobiology","Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774217300053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774217300053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T14:52:51Z","timestamp":1568818371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774217300053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9780128097144"],"references-count":100,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2017.01.005","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}